Literature DB >> 20638030

Chronic hepatitis B: past, present, and future.

Michelle Lai1, Yun-Fan Liaw.   

Abstract

There have been major advances in the field of hepatitis B (HBV) over the last few decades. These advances have resulted in the understanding of the natural history of chronic HBV infection, effective vaccines against the virus, sensitive assays for screening and monitoring of treatment, and effective treatments for viral suppression, all leading to improved outcomes. Debates and controversies remain, however, over the ideal management strategies of patients with chronic hepatitis B. To eradicate HBV, the global community needs to improve current preventive, screening, and treatment strategies. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20638030     DOI: 10.1016/j.cld.2010.05.003

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  10 in total

1.  Comparison of three Roche hepatitis B virus viral load assay formats.

Authors:  Michael T Pyne; Lauren Vest; Jennifer Clement; Jessica Lee; Jessica R Rosvall; Kevin Luk; Michael Rossi; Bryan Cobb; David R Hillyard
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

Review 2.  Induced immunity against hepatitis B virus.

Authors:  Zeinab Nabil Ahmed Said; Kouka Saadeldin Abdelwahab
Journal:  World J Hepatol       Date:  2015-06-28

3.  Provider, Patient, and Practice Factors Shape Hepatitis B Prevention and Management by Primary Care Providers.

Authors:  Nizar A Mukhtar; Priya Kathpalia; Joan F Hilton; Gene Lau; Albert Yu; Kevin Grumbach; Tung T Nguyen; Daniel Chan; Mandana Khalili
Journal:  J Clin Gastroenterol       Date:  2017-08       Impact factor: 3.062

4.  Influence of age and HBeAg status on the correlation between HBV DNA and hepatic inflammation and fibrosis in chronic hepatitis B patients.

Authors:  Han Bai; Hongbo Liu; Xiaokai Chen; Chan Xu; Xiaoguang Dou
Journal:  Dig Dis Sci       Date:  2012-11-22       Impact factor: 3.199

5.  Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations.

Authors:  Lucila Cassino; Silvina Benetti; Fabian Fay; Hugo Tanno; Jorge Quarleri
Journal:  BMC Infect Dis       Date:  2011-06-22       Impact factor: 3.090

6.  The Role of Antiviral Therapy for HBV-Related Hepatocellular Carcinoma.

Authors:  Liang-He Yu; Nan Li; Shu-Qun Cheng
Journal:  Int J Hepatol       Date:  2011-05-30

7.  CDC42-Interacting Protein 4 Gene Is Down Trans-Regulated by HBV DNA polymerase Trans Activated Protein 1.

Authors:  Yongzhi Lun; Chongbo Xu; Qing Chi; Xuelei Wang; Wen Sui; Sujuan Jiang
Journal:  Iran J Public Health       Date:  2014-03       Impact factor: 1.429

Review 8.  The immunopathogenetic role of autoantibodies in canine autoimmune hepatitis: lessons to learn from human autoimmune hepatitis.

Authors:  Christos Liaskos; Athanasios Mavropoulos; Timoklia Orfanidou; Vassiliki Spyrou; Labrini V Athanasiou; Charalambos Billinis
Journal:  Auto Immun Highlights       Date:  2012-10-09

9.  Performance verification and comparison of TianLong automatic hypersensitive hepatitis B virus DNA quantification system with Roche CAP/CTM system.

Authors:  Ming Li; Lin Chen; Li-Ming Liu; Yong-Li Li; Bo-An Li; Bo Li; Yuan-Li Mao; Li-Fang Xia; Tong Wang; Ya-Nan Liu; Zheng Li; Tong-Sheng Guo
Journal:  World J Gastroenterol       Date:  2017-10-07       Impact factor: 5.742

10.  Differences in metabolites of different tongue coatings in patients with chronic hepatitis B.

Authors:  Yu Zhao; Xiao-Jun Gou; Jian-Ye Dai; Jing-Hua Peng; Qin Feng; Shu-Jun Sun; Hui-Juan Cao; Ning-Ning Zheng; Jun-Wei Fang; Jian Jiang; Shi-Bing Su; Ping Liu; Yi-Yang Hu; Yong-Yu Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-17       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.